Here is what I’m reading in the world of medicine this morning:
- Barely five months into 2018, investors have placed more Seed and Series A money into biotherapeutics companies than all of last year.
- Epinephrine auto-injectors: to prescribe or not to prescribe. Do we need Epi-pens?
- Discovery will impact design of drug delivery systems at the molecular level
- Hunting a cure, Spark reports steady progress on hemophilia B gene therapy as Pfizer preps for pivotal handoff
Have a great day!
MattCorc 